The Complete Guide To Health .com
ENTER YOUR SEARCH BELOW...
  • HOME
  • Overview
  • ThePeoplesProtocol
  • UNITED STATES DOCTOR DIRECTORY
  • CALIFORNIA
  • WISCONSIN
  • GLOBAL DOCTOR DIRECTORY
  • Sublingual Ivermectin
  • UninformedConsent
  • Videos
  • ClinicalTrials
  • The BCP Protocol
  • DoctorAllanLandrito
  • DoctorBruceBoros
  • DoctorGustavoAguirre
  • DoctorJeanJacquesRajter
  • DoctorJenniferHibberd
  • DoctorKalpanaPatel
  • DoctorMobeenSyed
  • DoctorSabineHazan
  • FAQ
  • BrandolinisLaw
  • .
  • Vitamin C (Liposomal or Intravenous) Can Save Your Life
  • COVID-19 Is A Vitamin D Deficiency Disease
  • Despite what you have been MISLED to believe, antibiotics DO have anti-viral effects!
  • IVERMECTIN FOR THE PREVENTION OF COVID-19 So WHO is telling the Truth?
  • French company seeks to profit from COVID-19
  • Artemisia
  • Melatonin
  • Standard Of Care?
  • .
  • Ivermectin
    • CLICK HERE FOR ALL AREAS
    • A-E >
      • ARGENTINA
      • AUSTRALIA
      • BANGLADESH
      • BOLIVIA
      • BRAZIL
      • COSTA RICA
      • DOMINICAN REPUBLIC
      • EL SALVADOR
      • ETHIOPIA
    • F-Z >
      • FLORIDA
      • GUATEMALA
      • HONDURAS
      • HUNGARY
      • INDIA
      • LOUISIANA
      • PANAMA
      • PERU
      • PHILIPPINES
  • Ivermectina
  • IvermectinArticles
  • IvermectinBePrepared
  • IvermectinCautions
  • IvermectinCovexit
  • IvermectinEmail
  • IvermectinHowItWorks
  • IvermectinNutrition
  • IvermectinaPeru
  • IvermectinProductInfo
  • IvermectinProphylaxis
  • IvermectinProtocols
  • IvermectinResearch
  • IvermectinSkyNews
  • IvermectinSocialMedia
  • IvermectinTestimonials
  • IvermectinTheRealDeal
  • IvermectinTraining
  • IvermectinTrialSiteNews
  • IvermectinWhitePaper
  • .
  • OTHER VALUABLE WEBSITES
  • COVEXIT
  • DR BEEN
  • FLCCC
  • IVMMeta
  • TrialSiteNews
  • WhiteboardDoctor
  • .
  • POSITIVE MEDIA COVERAGE
  • Articles
  • TheConvoCouch
  • David Degraw has been a leading voice in the campaign to raise awareness about Ivermectin
  • LeeCamp
  • SkyNews
  • .
  • COVID-19: Disease or Metaphor?
  • FacebookCensorship
  • Get Up Stand Up
  • Hydroxychloroquine
  • SMS
  • SpreadTheWord
  • The Next Toilet Paper?
  • .
  • Mectizan
  • PLANNEDemic
  • Why home treatment of COVID-19 with several drugs is crucial
  • .
  • CRIMES AGAINST HUMANITY
  • PETITIONS
  • .
  • MATRIX
  • HELP NEEDED
  • CONTACT

/IvermectinResearch

Picture
   
Picture
​Ivermectin is a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. Molecular Formula: C48H74O14   Molecular Weight: 875.1 g/mol
​
  
   

​The story of how ivermectin was discovered is quite incredible. In the late 1960s, Satoshi Ōmura, a microbiologist at Tokyo’s Kitasako Institute, was hunting for new antibacterial compounds and started to collect thousands of soil samples from around Japan. He cultured bacteria from the samples, screened the cultures for medicinal potential, and sent them 10,000 km away to Merck Research Labs in New Jersey, where his collaborator, William Campbell, tested their effect against parasitic worms affecting livestock and other animals.

One culture, derived from a soil sample collected near a golf course southwest of Tokyo, was remarkably effective against worms. The bacterium in the culture was a new species, and was baptised 
Streptomyces avermictilis. The active component, named avermectin, was chemically modified to increase its activity and its safety.

​The new compound, called ivermectin, was commercialised as a product for animal health in 1981 and soon became a 
top-selling veterinary drug in the world. Remarkably, despite decades of searching, S. avermictilis remains the only source of avermectin ever found.
https://www.isglobal.org/en/healthisglobal/-/custom-blog-portlet/ivermectina-del-suelo-a-las-lombrices-y-mas-alla/3098670/0
 
Picture

​The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. 

"We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h."
​Caly, L., Druce, J., Catton, M., Jans, D. & Wagstaff, K. (2020). 
Antiviral Research Volume 178, June 2020, 104787. https://doi.org/10.1016/j.antiviral.2020.104787
https://www.sciencedirect.com/science/article/pii/S0166354220302011
https://doi.org/10.1016/j.antiviral.2020.104787
the_fda-approved_drug_ivermectin_inhibits_the_replication_of_sars-cov-2_in_t_vitro.pdf
File Size: 454 kb
File Type: pdf
Download File


​Clinical Studies:
​

Scheim, David.
“
Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion.” Available at SSRN 3636557 (2020).
“Overall mortality was 15% in the IVM group, 40% less (p=0.03) than the 25.2% mortality in the control group. For 75 patients with severe pulmonary disease (receiving oxygen at FiO2 ≥ 50% or ventilation), those treated with IVM (n=46) had a mortality of 38.8%, 52% less (p=0.001) than the 80.7% mortality in corresponding controls (n=29). Stabilization and then improvement often proceeded in 1-2 days, even for patients who had been deteriorating rapidly from room air to supplemental oxygen at up to a 50% mixture (FiO2 ≤ 0.5). The 1-2-day reversals of declining oxygen status in these Florida patients is consistent with rapid absorption and distribution into tissue of orally administered IVM.”

Chowdhury, Abu Taiub Mohammed Mohiuddin, et al.
“A comparative observational study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients.” ResearchGate.net
Conclusion: “Concerning the treatment outcome, adverse effect, and safety, IvermectinDoxycycline combination is superior to Hydroxychloroquine-Azithromycin therapy in the case of mild to moderate degree of COVID19 patients. ”
​
A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients

"All subjects in the Ivermectin-Doxycycline group (group A) reached a negative PCR for SARS-CoV2, at a mean of 8.93days, and all reached symptomatic recovery, at a mean of 5.93days, with 55.10% symptom-free by the 5th day."
https://www.researchsquare.com/article/rs-38896/v1
a_randomized_trial_of_ivermectin-doxycycline_and_hydroxychloroquine-azithromycin_therapy_on_covid19_patients.pdf
File Size: 604 kb
File Type: pdf
Download File


Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)

​
"This preliminary pilot study demonstrated for the first time that add-on use of IVM to HCQ and AZT had obvious higher cure rate, shorter hospital stay days compared with controls. In addition, there was no obvious reported adverse events."
https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1
effectiveness_of_ivermectin_as_add-on_therapy_in_covid-19_management.pdf
File Size: 560 kb
File Type: pdf
Download File

Gorial, Faiq I., et al.
​“
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial).” medRxiv (2020).
~ All the patients of IVM group were cured; none of the Ivermectin patients died. “The mean time to stay in the hospital was significantly lower in IVM group compared with the controls”, 7.62 days for IVM and 13.22 days for control. Results were highly statistically significant.

A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline

"Combination of Ivermectin and doxycycline was found to be very effective in viral clearance in mild and moderately sick COVID-19 patients. Retesting was done between 4 and 18 days of starting medication. All patients tested negative and their symptoms improved within 72 hours. There were no noticeable side effects."
ICON (Ivermectin in COvid Nineteen) Study: Use of Ivermectin Is Associated with Lower Mortality in Hospitalized Patients with COVID-19
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3631261
https://www.researchgate.net/publication/343305357
ttps://www.banglajol.info/index.php/JBCPS/article/view/47512
acaseseriesof100covid-19positivepatientstreatedwithcombinationofivermectinanddoxycycline.pdf
File Size: 1164 kb
File Type: pdf
Download File


ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19

"The primary outcome was all-cause in-hospital mortality. Univariate analysis showed lower mortality in the ivermectin group (15.0% versus 25.2%)."
https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2
Rajter, Juliana Cepelowicz, et al. “ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19.” medRxiv (2020). medRxiv.org
Conclusion: “Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support.”
icon__ivermectin_in_covid_nineteen__study-_use_of_ivermectin_is_associated_with_lower_mortality_in_hospitalized_patients_with_covid19_.pdf
File Size: 129 kb
File Type: pdf
Download File


​Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients

"Viral clearance is 66% on day 5 and 83.5% on day 6."
https://www.banglajol.info/index.php/JBCPS/article/view/47514
comparison_of_viral_clearance_between_ivermectin_with_doxycycline_and_hydroxychloroquine_with_azithromycin_in_covid-19_patients.pdf
File Size: 194 kb
File Type: pdf
Download File


A comparative observational study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID-19 patients.

 "All subjects in the Ivermectin-Doxycycline group (group A) reached a negative PCR for SARS-CoV-2, at a mean of 8.93days, and all reached symptomatic recovery, at a mean of 5.93days, with 55.10% symptom-free by the 5th day." 

​Abu Taiub Mohammed Mohiuddin Chowdhury, Mohammad Shahbaz, Md. Rezaul Karim, Jahirul Islam, Guo Dan, He Shuixiang (June 2020). 
DOI: 10.13140/RG.2.2.22193.81767 
https://www.researchgate.net/publication/342159343
a_comparative_observational_study_on_ivermectin-_doxycycline_and_hydroxychloroquine-azithromycin_therapy_on_covid19_patients..pdf
File Size: 613 kb
File Type: pdf
Download File

These two papers seem to be based on the same study.
​
"A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients." (2020). 

​Researchsquare preprint.
​Chowdhury, Abu Taiub Mohammed Mohiuddin, Mohammad Shahbaz, Md Rezaul Karim, Johirul Islam, Dan Guo, and Shuixiang He. 

DOI: https://doi.org/10.21203/rs.3.rs-38896/v1 - Posted 14 July. 
https://www.researchsquare.com/article/rs-38896/v1
a_randomized_trial_of_ivermectin-doxycycline_and_hydroxychloroquine-azithromycin_therapy_on_covid19_patients.pdf
File Size: 604 kb
File Type: pdf
Download File


Antimalarials for COVID-19 Treatment: Rapid Reversal of Oxygen Status Decline with the Nobel Prize-Honored Macrocyclic Lactone Ivermectin (June 3, 2020).

​Scheim, David 
https://ssrn.com/abstract=3617911
http://dx.doi.org/10.2139/ssrn.3617911

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3617911
antimalarials_for_covid-19_treatment_-_rapid_reversal_of_oxygen_status_decline_with_the_nobel_prize-honored_macrocyclic_lactone_ivermectin.pdf
File Size: 417 kb
File Type: pdf
Download File


Mode of Action:
 
  
Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick—A Literature Review
https://www.mdpi.com/2218-0532/88/3/36
antiviral_activity_of_ivermectin_against_sars-cov-2_an_old-fashioned_dog_with_a_new_trick—_a_literature_review.pdf
File Size: 562 kb
File Type: pdf
Download File


​Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. 
Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA.
Biochem J. 2012;443:851–6.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327999/
https://pubmed.ncbi.nlm.nih.gov/22417684/

​The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer. 
Yang SNY, Atkinson SC, Wang C, et al.
Antivir Res. 2020;177:104760.
https://www.sciencedirect.com/science/article/abs/pii/S0166354219307211
https://pubmed.ncbi.nlm.nih.gov/32135219/

Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral Agent
https://chemrxiv.org/articles/preprint/12782258
ivermectin_arxiv.pdf
File Size: 3728 kb
File Type: pdf
Download File

si_final.pdf
File Size: 3757 kb
File Type: pdf
Download File


A Combination of Ivermectin and Doxycycline Possibly Blocks the Viral Entry and Modulate the Innate Immune Response in COVID-19 Patients. 
Maurya, Dharmendra Kumar (2020):
ChemRxiv. Preprint.

https://doi.org/10.26434/chemrxiv.12630539.v1
​
https://chemrxiv.org/articles/A_Combination_of_Ivermectin_and_Doxycycline_Possibly_Blocks_the_Viral_Entry_and_Modulate_the_Innate_Immune_Response_in_COVID-19_Patients/12630539/1
a_combination_of_ivermectin_and_doxycycline_possibly_blocks_the_viral_entry_and_modulate_the_innate_immune_response_in_covid-19_patients.pdf
File Size: 1972 kb
File Type: pdf
Download File


Binding Mechanism and Structural Insights into the Identified Protein Target of Covid-19 with In-Vitro Effective Drug Ivermectin.

Sen Gupta, Parth Sarthi; Biswal, Satyaranjan; Panda, Saroj Kumar; Ray, Abhik Kumar; Rana, Malay Kumar (2020):

ChemRxiv. Preprint.
https://doi.org/10.26434/chemrxiv.12463946.v1
https://chemrxiv.org/articles/Binding_Mechanism_and_Structural_Insights_into_the_Identified_Protein_Target_of_Covid-19_with_In-Vitro_Effective_Drug_Ivermectin/12463946/1
ivermectin_manuscript_v1.pdf
File Size: 3175 kb
File Type: pdf
Download File

supporting_information.pdf
File Size: 1151 kb
File Type: pdf
Download File


Immunological mechanisms explaining the role of IgE, mast cells, histamine, elevating ferritin, IL-6, D-dimer, VEGF levels in COVID-19 and dengue, potential treatments such as mast cell stabilizers, antihistamines, Vitamin C, hydroxychloroquine, ivermectin and azithromycin. 

Arumugham, Vinu. (2020, April 11). Zenodo. http://doi.org/10.5281/zenodo.3748304 
immunological_mechanisms_explaining_the_role_of_ige_mast_cells_histamine_elevating_ferritin_il-6_d-dimer_vegf_levels_in_covid-19.pdf
File Size: 96 kb
File Type: pdf
Download File


Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.
Emanuele Rizzo (2020) Naunyn Schmiedebergs Arch Pharmacol. 2020 May 27 : 1–4. doi: 10.1007/s00210-020-01902-5 [Epub ahead of print] PMCID: PMC7251046 - PMID: 32462282 ​
https://pubmed.ncbi.nlm.nih.gov/32462282/
https://link.springer.com/article/10.1007/s00210-020-01902-5
ivermectin_antiviral_properties_and_covid-19-_a_possible_new_mechanism_of_action.pdf
File Size: 341 kb
File Type: pdf
Download File



​   
Summary and Analysis:
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
https://www.nature.com/articles/s41429-020-0336-z
ivermectin-_a_systematic_review_from_antiviral_effects_to_covid-19_complementary_regimen.pdf
File Size: 643 kb
File Type: pdf
Download File


Picture
​​Ivermectin for Covid-19
https://www.researchgate.net/publication/342170742_Ivermectin_for_Covid-19
September 2020 version:
ivermectin-18.pdf
File Size: 598 kb
File Type: pdf
Download File

Older version.:
ivermectin_summary_and_analysis_by_amelia_carolina_sparavigna.pdf
File Size: 538 kb
File Type: pdf
Download File


Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.
“Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2.”
​
Fatemeh Heidary and Reza Gharebaghi (2020). J Antibiot (Tokyo). 2020 Jun 12 : 1–10. doi: 10.1038/s41429-020- 0336-z [Epub ahead of print] - PMCID: PMC7290143 

https://www.nature.com/articles/s41429-020-0336-z
ivermectin-_a_systematic_review_from_antiviral_effects_to_covid-19_complementary_regimen.pdf
File Size: 643 kb
File Type: pdf
Download File


Other Studies:


Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects
https://pubmed.ncbi.nlm.nih.gov/12362927/

The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19
Virginia D Schmith, Jie Zhou, Lauren RL Lohmer (2020). medRχiv prepint posted April 26, 2020. doi:
https://pubmed.ncbi.nlm.nih.gov/32378737/
the_approved_dose_of_ivermectin_alone_is_not_the_ideal_dose_for_the_treatment_of_covid-19.pdf
File Size: 417 kb
File Type: pdf
Download File


Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. 

​R. Choudhary and A.K. Sharma (2020). New Microbes New Infect. 2020 May; 35: 100684. Published online 2020 Apr 22. doi: 10.1016/j.nmni.2020.100684 -PMCID: PMC7175902 - PMID: 32322397

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175902/ 
​
https://pubmed.ncbi.nlm.nih.gov/32322397/
​
https://www.sciencedirect.com/science/article/pii/S2052297520300366

potential_use_of_hydroxychloroquine_ivermectin_and_azithromycin_drugs_in_fighting_covid-19_trends_scope_and_relevance.pdf
File Size: 578 kb
File Type: pdf
Download File


 
Neurological associations of COVID-19.
​
Mark A Ellul, Laura Benjamin, Bhagteshwar Singh, Suzannah Lant, Benedict Daniel Michael, Ava Easton, Rachel Kneen, Sylviane Defres, Jim Sejvar, and Tom Solomon,  Lancet Neurol. 2020 Jul 2 - doi: 10.1016/S1474-4422(20)30221-0 - PMCID: PMC7332267 - PMID: 32622375
COVID-19 strains remote regions of Peru.
Barbara Fraser (2020). The Lancet Journal - WORLD REPORT| VOLUME 395, ISSUE 10238, P1684, MAY 30, 2020 - Published: May 30, 2020 

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31236-8/fulltext
Therapeutic potential of ivermectin for COVID-19.
Kalyne Gonçalves, Amanda Vasconcelos, Davi Barbirato, et al.  Authorea. May 26, 2020. DOI: 10.22541/au.159050476.60928563 
​
Ivermectin and COVID- 19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses
Mike Bray, Craig Rayner, François Noël, David Jans, and Kylie Wagstaff.  Antiviral Res. 2020 Jun; 178: 104805. Published online 2020 Apr 21. doi: 10.1016/j.antiviral.2020.104805 - PMCID: PMC7172803 - PMID: 32330482 
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
Faiq I. Gorial, Sabeeh Mashhadani, Hend M Sayaly, Basim Dhawi Dakhil, Marwan M AlMashhadani, Adnan M Aljabory, , Hassan M Abbas, Mohammed Ghanim, Jawad I Rasheed - 8 July 2020 - doi: https://doi.org/10.1101/2020.07.07.20145979 
Ivermectin: potential candidate for the treatment of Covid 19.
Gupta, D., Sahoo, A. K., & Singh, A. (2020). The Brazilian Journal of Infectious Diseases. Braz J Infect Dis. 2020 Jun 28 - doi: 10.1016/j.bjid.2020.06.002 [Epub ahead of print] - PMCID: PMC7321032 - PMID: 32615072 
Practice considerations on the use of investigational anti‐COVID‐ 19 medications: Dosage, administration and monitoring.
Kang, J. E., & Rhie, S. J. (2020). Journal of Clinical Pharmacy and Therapeutics. 2020 Jun 11 : 10.1111/jcpt.13199. doi: 10.1111/jcpt.13199 [Epub ahead of print] - PMCID: PMC7307068 - PMID: 32524645
A Wonder Drug in the Arsenal against COVID-19: Medication Evidence from Ivermectin.
Kumar, B. S., Jeyaraman, M., Jain, R., & Anudeep, T. C. (2020).  Journal of Advances in Medicine and Medical Research, 30-37. 
COVID-19 and the rush for self-medication and self-dosing with ivermectin: A word of caution.
Marcelo Beltrão Molento.  One Health. 2020 Dec; 10: 100148. Published online 2020 Jun 24. doi: 10.1016/j.onehlt.2020.100148 - PMCID: PMC7313521 - PMID: 32632377

Ivermectin for COVID-19: A living systematic review protocol
Luis E. Ortiz-Muñoz, Francisca Verdugo, Rocío Bravo-Jeria, Macarena Morel-Marambio, María Paz Acuña, Gabriel Rada - June 2020 -DOI: 10.31219/osf.io/xsgke 
Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. 
Pandey, A., Nikam, A.N., Shreya, A.B., Mutalik, S.P., Gopalan, D., Kulkarni, S., Padya, B.S., Fernandes, G., Mutalik, S. and Prassl, R. (2020). Life Sci. 2020 Sep 1; 256: 117883. Published online 2020 Jun 1. doi: 10.1016/j.lfs.2020.117883 - PMCID: PMC7263255 - PMID: 32497632 ​
Patrì A, Fabbrocini G. Hydroxychloroquine and ivermectin: a synergisticcombination for COVID- 19 chemoprophylaxis and/or treatment?
J Am Acad Dermatol. 2020 Jun; 82(6): e221. Published online 2020 Apr 10. doi: 10.1016/j.jaad.2020.04.017 - PMCID: PMC7146719 - PMID: 32283237 
Drug repurposing clinical trials in the search for life-saving Covid-19 therapies; research targets and methodological and ethical issues. 
Paumgartten, F.J.R., Delgado, I.F., da Rocha Pitta, L. and de Oliveira, A.C.A.X., 2020. Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia. https://doi.org/10.22239/2317-269x.01596 

The current understanding and potential therapeutic options to combat COVID-19.
Pooladanda, V., Thatikonda, S., & Godugu, C. (2020).  Life Sciences, 117765. 
Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion​
Scheim, David, (June 26, 2020). Available at SSRN: 
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3636557
Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19
Khan Sharun, Kuldeep Dhama, Shailesh Kumar Patel, Mamta Pathak, Ruchi Tiwari, Bhoj Raj Singh, Ranjit Sah, D. Katterine Bonilla-Aldana, Alfonso J. Rodriguez-Morales, and Hakan Leblebicioglu (2020).  Ann Clin Microbiol Antimicrob. 2020; 19: 23. Published online 2020 May 30. doi: 10.1186/s12941-020-00368-w - PMCID: PMC7261036 - PMID: 32473642 
Ivermectin: Is It to Be a Potent Therapeutic Option for COVID-19? 
Shweta Sinha, Alka Sehgal, Rakesh Sehgal. - June 2020 - DOI: 10.14740/cii106 
Ivermectina para el tratamiento de la infección COVID-19
Ruth Jimbo Sotomayor, Xavier SánchezXavier Sánchez, Ana Maria Gomez Jaramillo, Felipe Moreno-Piedrahita.  - May 2020 -Report number: 12 Affiliation: Pontificia Universidad Católica del Ecuador - Project: Evaluación de Tecnologías Sanitarias COVID-19 
Ivermectin as a Potential Therapeutic Agent for COVID-19–case studies. 
Wijaya, N. S., & Salim, S. (2020). Cermin Dunia Kedokteran, 47(7), 370-372.
Antimalarials for COVID-19 Treatment: Rapid Reversal of Oxygen Status Decline with the Nobel Prize-Honored Macrocyclic Lactone Ivermectin​
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3617911
   
Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19
​https://openheart.bmj.com/content/7/2/e001350

Ivermectin Molecular Docking Studies
Dayer, Mohammad Reza.
“Coronavirus (2019-nCoV) Deactivation via Spike Glycoprotein Shielding by Old Drugs, Bioinformatic Study.”

https://www.preprints.org/manuscript/202005.0020/v1

~ Ivermectin was the second most effective drug at shielding the Spike from the ACE2 receptor.
Thurakkal, Liya, et al.
“An in-silico study on selected organosulfur compounds as potential drugs for SARS-CoV-2 infection via binding multiple drug targets.”
​
Download PDF file
Conclusion: Ivermectin inhibits the helicase polymerase of SARS-CoV-2 (-8.5)
Hussien, Mostafa A., and Ahmed EM Abdelaziz.
“Molecular Docking suggests repurposing of Brincidofovir as a potential drug targeting SARS-CoV-2″ COVID-19″ ACE2 receptor and main protease.”

https://europepmc.org/article/ppr/ppr177413
Conclusion: Ivermectin inhibits Mpro and ACE2 (-10.31 and -8.62).
Rehman, Md Tabish, Mohamed F. AlAjmi, and Afzal Hussain.
“Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19.”

https://europepmc.org/article/ppr/ppr169871
Conclusion: Ivermectin inhibits Mpro (-9.3 docking score).
Suravajhala, Renuka, et al.
“Comparative Docking Studies on Curcumin with COVID-19 Proteins.”

https://www.preprints.org/manuscript/202005.0439/v3
Conclusion: Ivermectin inhibits the Spike, M-protein, N-protein, Nsp10 (-6.69, -7.42, -7.11, -9.82).
Dasgupta, Jhimli, et al.
“Nsp7 and Spike Glycoprotein of SARS-CoV-2 are envisaged as Potential Targets of Vitamin D and Ivermectin.”

https://www.preprints.org/manuscript/202005.0084/v1
Conclusion: Ivermectin inhibits Spike protein (-15 kcal/mole).
Giri, Sabeena, Arnica F. Lal, and Shaminder Singh.
“Battle against Coronavirus: Repurposing old friends (Food borne polyphenols) for new enemy (COVID-19).”

https://tinyurl.com/12108546
Conclusion: Ivermectin inhibits Mpro (-8.2).
​

Nallusamy, Saranya, et al.
“Shortlisting Phytochemicals Exhibiting Inhibitory Activity against Major Proteins of SARS-CoV-2 through Virtual Screening.”
https://europepmc.org/article/ppr/ppr168910
Conclusion: Ivermectin inhibits Mpro, RdRp, Spike (-7.3, -9.4, -8.2).
​
Maurya, Dharmendra Kumar.
​“
A Combination of Ivermectin and Doxycycline Possibly Blocks the Viral Entry and Modulate the Innate Immune Response in COVID-19 Patients.” (2020).
~ In this molecular docking study, the mechanism of action of ivermectin and doxycycline were examined. Ivermectin is a strong inhibitor of replicase (RdRp), both proteases, the N-protein, and the Spike protein. The Ki values for ivermectin against various SARS-CoV-2 targets was below 1.0 and in some cases below 0.4 micromolar.
​

Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral Agent​
https://chemrxiv.org/articles/preprint/12782258

​Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment
https://onlinelibrary.wiley.com/doi/10.1002/jcp.30055

This study is not specifically about the use of ivermectin to treat patients with COVID-19. However, it does point out the fact that Ivermectin is considered safe.

Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30790-4/fulltext
 

​
The links listed below are in need of review. There is a lot to do. I will review them as soon as I can:


​

https://ivmmeta.com/ivm-meta.pdf



https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Ivermectin-in-the-prophylaxis-and-treatment-of-COVID-19.pdf



https://www.sciencedirect.com/science/article/pii/S1201971220325066/pdf



https://www.researchsquare.com/article/rs-109670/v1.pdf



https://www.medrxiv.org/content/10.1101/2020.11.16.20232223v1.full.pdf



http://iaimjournal.com/wp-content/uploads/2020/10/iaim_2020_0710_23.pdf



https://www.researchsquare.com/article/rs-100956/v2.pdf



https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1.full.pdf



https://www.medrxiv.org/content/10.1101/2020.10.26.20219345v1.full.pdf



https://www.sciencedirect.com/science/article/pii/S0012369220348984/pdf



https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v1.full.pdf



https://www.sciencedirect.com/science/article/pii/S030028962030288X



https://www.medrxiv.org/content/10.1101/2020.09.10.20191619v1.full.pdf



https://clinicaltrials.gov/ProvidedDocs/61/NCT04422561/Prot_SAP_000.pdf



https://www.medrxiv.org/content/10.1101/2020.08.12.20170282v1.full.pdf



https://www.researchgate.net/profile/Rishad_Choudhury_Robin/publication/343305357_A_Case_Series_of_100_COVID-19_Positive_Patients_Treated_with_Combination_of_Ivermectin_and_Doxycycline/links/5f23b82c458515b729f5e600/A-Case-Series-of-100-COVID-19-Positive-Patients-Treated-with-Combination-of-Ivermectin-and-Doxycycline.pdf



http://bcpsjournal.org/mhcms-admin/media/pdf/article761.pdf



https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1.full.pdf

NAVIGATION:
PLEASE EXPLORE
​THE OTHER PAGES
ON THIS WEBSITE:

​
HOME
OVERVIEW
CLINICAL TRIALS
FAQ
VITAMIN D DEFICIENCY DISEASE
ANTIBIOTICS VS. VIRUSES
VITAMIN C CAN SAVE YOUR LIFE
DISEASE OR METAPHOR?
   
​IVERMECTIN
ARGENTINA
AUSTRALIA
BANGLADESH
BOLIVIA
BRAZIL
COSTA RICA
DOMINICAN REPUBLIC
EL SALVADOR
ETHIOPIA
GUATEMALA
HONDURAS
HUNGARY
INDIA
PANAMA
PERU
PHILLIPINES
 
 IVERMECTINA
   
ARTICLES
BE PREPARED
BRANDOLINIS LAW
CAUTIONS
COVEXIT
DAVID DEGRAW
DOCTOR BRUCE BOROS
EMAIL TO DOCTORS
FACEBOOK CENSORSHIP
GET UP STAND UP
HOW IT WORKS
NUTRITION
PRODUCT INFO
PROPHYLAXIS
PROTOCOLS
RESEARCH
SKY NEWS
SMS
SOCIAL MEDIA
SPREAD THE WORD
TESTIMONIALS
THE NEXT TOILET PAPER
THE REAL DEAL
TRAINING
TRIAL SITE NEWS
WHITE PAPER
CONTACT
   
UNITED STATES DOCTOR DIRECTORY
  • GLOBAL DOCTOR DIRECTORY
   
CRIMES AGAINST HUMANITY
WHITE HOUSE PETITION
  
MATRIX



​DISCLAIMER:
THE INFORMATION
ON THIS WEBSITE IS FOR
​INFORMATIONAL PURPOSES ONLY.

​
I AM NOT RECOMMENDING
THAT PEOPLE TAKE IVERMECTIN
OR ANY OTHER MEDICATION.

I AM RECOMMENDING
THAT EVERYONE SHARE THIS
INFORMATION WITH THEIR DOCTOR
SO THAT THEY CAN LEARN
​MORE ABOUT IVERMECTIN.

CONSULT WITH YOUR PREFERRED
HEALTH CARE PROFESSIONAL
TO DETERMINE WHAT IS
BEST FOR YOUR HEALTH.
    

​FINANCIAL DISCLOSURE:

I HAVE ABSOLUTELY
NO FINANCIAL STAKE
IN ANY BUSINESS
RELATED TO IVERMECTIN
OR COVID-19.

THIS IS A LABOR OF LOVE
THAT IS DONE
FOR THE GOOD OF ALL.



JAMES ROGUSKI
310-619-3055


​.
   
Picture



PLEASE SHARE THIS INFORMATION
WITH EVERYONE YOU POSSIBLY CAN.
​

​